Publications by authors named "Michelle Sy"

Claim this Profile
M
MSH3 is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism.
Alan Mejia Maza, Madison Hincher, Kevin Correia, Tammy Gillis, Ayumi Nishiyama, Michelle Sy

Am J Hum Genet· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A hexamer tandem repeat RNA embedded within an SVA retrotransposon drives R-loop formation and neurodegeneration.
Laura D'Ignazio, Alan P R Lorenzetti, Ellen B Penney, Taylor A Evans, Bareera Qamar, Michelle Sy

Cell Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelin pathology is a key feature of X-linked Dystonia Parkinsonism.
Priya Prakash, Kerry C Limberg, Weimin Zhang, Yu Zhao, Klaudia F Laborc, Michelle Sy

bioRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic targeting of alternative splicing caused by a lethal noncoding structural variant in X-linked dystonia parkinsonism.
Rachita Yadav, Christine A Vaine, Aloysius Domingo, Siddharth Reed, Shivangi Shah, Michelle Sy

medRxiv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A hexamer tandem repeat RNA embedded within an SVA retrotransposon drives R-loop formation and neurodegeneration.
Laura D'Ignazio, Alan P R Lorenzetti, Ellen B Penney, Taylor A Evans, Bareera Qamar, Michelle Sy

Cell Rep· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
is a genetic modifier of somatic repeat instability in X-linked dystonia parkinsonism.
Alan Mejia Maza, Madison Hincher, Kevin Correia, Tammy Gillis, Ayumi Nishiyama, Michelle Sy

bioRxiv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic innovations for the symptomatic treatment of Parkinson's disease: focus on technology-based therapies.
Jeryl Ritzi T Yu, Avery Kundrick, Enrique C Panganiban, Michelle Ann Sy, Saar Anis

J Neural Transm (Vienna)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Myeloperoxidase to Reduce Neuroinflammation in X-Linked Dystonia Parkinsonism.
Tiziana Petrozziello, Negin Jalali Motlagh, Ranee Zara B Monsanto, Dan Lei, Micaela G Murcar, Michelle Sy

CNS Neurosci Ther· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting myeloperoxidase to reduce neuroinflammation in X-linked dystonia parkinsonism.
Tiziana Petrozziello, Negin J Motlagh, Ranee Z B Monsanto, Dan Lei, Micaela G Murcar, Michelle Sy

medRxiv· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neuroectodermal Diseases: A Comparative Case Report Study.
John Paul M Cruz, Michelle Sy

Cureus· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dystonia and leveraging oral pharmacotherapy.
Michelle Ann C Sy, Hubert H Fernandez

J Neural Transm (Vienna)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Treatment of Early Motor Manifestations of Parkinson Disease (PD).
Michelle Ann C Sy, Hubert H Fernandez

Neurotherapeutics· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis